In contrast, a 12-month open label study with nine individuals (eight men and one woman) diagnosed with AD, who received standard treatment with cholinesterase inhibitors, was performed in Germany by Hager et al. [59] Based on their results, the authors suggest that treatment with α-LA would be a successful neuroprotective option in AD, at least as an adjuvant to standard treatment with acetylcholinesterase inhibitors. The gene discussed is SSB; the disease is Alzheimer disease.